Bevantolol

Bevantolol
Clinical data
AHFS/Drugs.com	International Drug Names
Routes of; administration	Oral
ATC code	C07AB06 (WHO) ;
Identifiers
	IUPAC name (RS)-[2-(3,4-dimethoxyphenyl)ethyl][2-hydroxy-3-(3-methylphenoxy)propyl]amine;
CAS Number	59170-23-9 ;
PubChem CID	2372;
DrugBank	DB01295 ;
ChemSpider	2282 ;
UNII	34ZXW6ZV21;
ChEBI	CHEBI:238698 ;
ChEMBL	ChEMBL314010 ;
CompTox Dashboard (EPA)	DTXSID70860597 ;
Chemical and physical data
Formula	C20H27NO4
Molar mass	345.439 g·mol−1
3D model (JSmol)	Interactive image;
Chirality	Racemic mixture
	SMILES O(c1ccc(cc1OC)CCNCC(O)COc2cc(ccc2)C)C;
	InChI InChI=1S/C20H27NO4/c1-15-5-4-6-18(11-15)25-14-17(22)13-21-10-9-16-7-8-19(23-2)20(12-16)24-3/h4-8,11-12,17,21-22H,9-10,13-14H2,1-3H3 ; Key:HXLAFSUPPDYFEO-UHFFFAOYSA-N ;
	(verify)

Bevantolol (INN) was a drug candidate for angina and hypertension that acted as both a beta blocker and a calcium channel blocker.^[1]^[2] It was discovered and developed by Warner-Lambert^[3] but in January 1989 the company announced that it had withdrawn the New Drug Application; the company's chairman said: "Who needs the 30th beta blocker?"^[4] As of 2016^[update] it wasn't marketed in the US, UK, or Europe and the authors of a Cochrane review could find no product monograph for it.^[5]

References

^ Frishman WH, Goldberg RJ, Benfield P (January 1988). "Bevantolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris". Drugs. 35 (1): 1–21. doi:10.2165/00003495-198835010-00001. PMID 2894292.
^ Vaughan Williams EM (July 1987). "Bevantolol: a beta-1 adrenoceptor antagonist with unique additional actions". Journal of Clinical Pharmacology. 27 (7): 450–60. doi:10.1002/j.1552-4604.1987.tb03049.x. PMID 2888789. S2CID 72749127.
^ McPherson EM (2007). Pharmaceutical Manufacturing Encyclopedia (3rd ed.). Burlington: Elsevier. pp. 618–619. ISBN 9780815518563.
^ "Warner-Lambert Pipeline Narrowed to 40 Active Research Compounds". Pink Sheet. 30 January 1989.
^ Wong GW, Boyda HN, Wright JM (March 2016). "Blood pressure lowering efficacy of beta-1 selective beta blockers for primary hypertension". The Cochrane Database of Systematic Reviews. 3 (4): CD007451. doi:10.1002/14651858.CD007451.pub2. PMC 6486283. PMID 26961574.

This article about an amine is a stub. You can help Wikipedia by expanding it.

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.

[1] Frishman WH, Goldberg RJ, Benfield P (January 1988). "Bevantolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris". Drugs. 35 (1): 1–21. doi:10.2165/00003495-198835010-00001. PMID 2894292.

[2] Vaughan Williams EM (July 1987). "Bevantolol: a beta-1 adrenoceptor antagonist with unique additional actions". Journal of Clinical Pharmacology. 27 (7): 450–60. doi:10.1002/j.1552-4604.1987.tb03049.x. PMID 2888789. S2CID 72749127.

[3] McPherson EM (2007). Pharmaceutical Manufacturing Encyclopedia (3rd ed.). Burlington: Elsevier. pp. 618–619. ISBN 9780815518563.

[4] "Warner-Lambert Pipeline Narrowed to 40 Active Research Compounds". Pink Sheet. 30 January 1989.

[5] Wong GW, Boyda HN, Wright JM (March 2016). "Blood pressure lowering efficacy of beta-1 selective beta blockers for primary hypertension". The Cochrane Database of Systematic Reviews. 3 (4): CD007451. doi:10.1002/14651858.CD007451.pub2. PMC 6486283. PMID 26961574.

[1]

[2]

[3]

[4]

[5]

v t e Beta blockers (C07)
β, non-selective	Alprenolol Bopindolol Bupranolol Carteolol Cloranolol Mepindolol Nadolol Oxprenolol Penbutolol Pindolol/Iodopindolol Propranolol^# Sotalol Tertatolol Timolol^#
β₁-selective	Acebutolol Atenolol Betaxolol Bevantolol Bisoprolol^# Celiprolol Epanolol Esmolol Landiolol Metoprolol Nebivolol Practolol Talinolol
β₂-selective	Butaxamine
α₁- + β-selective	Arotinolol Carvedilol Labetalol
^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III